anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This project will target up to 25 ambulatory boys with DMD aged 7-13 years. Because the vascular impact of tadalafil is immediate, we will confirm that the drug target is valid target in lower extremities by assessing the change in post-exercise microvascular perfusion using Blood Oxygen Level-Dependent (BOLD) MRI or change in post-exercise hyperemia using Doppler ultrasonography. We will also assess the functional impact of the drug through exercise testing. Patients will be randomized to undergo the above-mentioned assessments with or without the study drug on two separate visits. Time function tests, MRI-based fat fraction and inflammation measurements will also be obtained in all patients, thus characterizing disease severity and provide a sampling of information on whether a subset of patients do not respond to the drug. This information may be used to inform future trials as to the appropriate target population for PDE5i as well as account for potential failures in a previously published phase 3 clinical trial.
Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
Stroke is the world's second-leading cause of death. Current treatments for cerebral edema following intracerebral hemorrhage (ICH) mainly involve hyperosmolar fluids, but this approach is often inadequate. Propolis, known for its various beneficial properties, especially antioxidant and anti-inflammatory properties, could potentially act as an adjunctive therapy and help alleviate stroke-associated injuries. The chemical composition of Geniotrigona thoracica propolis extract was analyzed by GC-MS after derivatization for its total phenolic and total flavonoid content. The total phenolic content and total flavonoid content of the propolis extract were 1037.31 ± 24.10 μg GAE/mL and 374.02 ± 3.36 μg QE/mL, respectively. By GC-MS analysis, its major constituents were found to be triterpenoids (22.4% of TIC). Minor compounds, such as phenolic lipids (6.7% of TIC, GC-MS) and diterpenic acids (2.3% of TIC, GC-MS), were also found. Ninety-six Sprague Dawley rats were divided into six groups; namely, the control group, the ICH group, and four ICH groups that received the following therapies: mannitol, propolis extract (daily oral propolis administration after the ICH induction), propolis-M (propolis and mannitol), and propolis-B+A (daily oral propolis administration 7 days prior to and 72 h after the ICH induction). Neurocognitive functions of the rats were analyzed using the rotarod challenge and Morris water maze. In addition, the expression of NF-κB, SUR1-TRPM4, MMP-9, and Aquaporin-4 was analyzed using immunohistochemical methods. A TUNEL assay was used to assess the percentage of apoptotic cells. Mannitol significantly improved cognitive-motor functions in the ICH group, evidenced by improved rotarod and Morris water maze completion times, and lowered SUR-1 and Aquaporin-4 levels. It also significantly decreased cerebral edema by day 3. Similarly, propolis treatments (propolis-A and propolis-B+A) showed comparable improvements in these tests and reduced edema. Moreover, combining propolis with mannitol (propolis-M) further enhanced these effects, particularly in reducing edema and the Virchow-Robin space. These findings highlight the potential of propolis from the Indonesian stingless bee, Geniotrigona thoracica, from the Central Tapanuli region as a neuroprotective, adjunctive therapy.
The invention comprises compounds of the general formula: <FORM:0863552/IV (b)/1> and their acid addition salts, wherein R1 is a methyl group, R2 is a hydrogen atom or an alkyl group (C1-4) and R3 + R4 is a trimethylene or tetramethylene group, thus forming a 5 or 6 membered ring with the carbon and the nitrogen atoms adjacent R4 and R3 respectively, and the preparation thereof by condensing a phenthiazine of the general formula:  <FORM:0863552/IV (b)/2> with a haloalkyl amine of the general formula:  <FORM:0863552/IV (b)/3> wherein X is a chlorine or bromine atom, if desired in the presence of an alkaline condensation agent and a solvent, and further if desired converting the base into an acid addition salt. 2-(N-Methyl-pyrrodidyl-21)-1- chlorolthaneis prepared from the corresponding ethanol by reaction with thionyl chloride. Specifications 802,726 and 863,547 also are referred to.ALSO:Pharmaceutical compositions comprise an inert diluent and compounds of the general formula <FORM:0863552/VI/1> or an acid addition salt thereof, wherein R1 is a methyl group, R2 is a hydrogen atom or a C1-4 alkyl group and R3 and R4 is a tri- or a tetramethylene group, thus forming a 5- or 6-membered ring with the carbon and the nitrogen atoms adjacent to R4 and R3, respectively. Compositions include tablets and solutions for both parenteral and local use.  Acid addition salts include the hydrochlorides, hydrobromides, sulphates, citrates, tartrates, succinates, maleates, acetates, benzoates and hexahydrobenzoates. Specifications 802,726 and 863,547 also are referred to.
Diabetes mellitus (DM) is common among persons experiencing homelessness (PEH), often inadequately managed, and carries significant costs. SMS strategies for DM have not been tested among PEH despite the accessibility of mobile phones. This study uses a SMS strategy to offer better communication, education, and information management; improve outreach; facilitate care coordination; explore barriers to care; and support behavior changes. This mixed-methods (RCT and qualitative) study will be implemented in shelter-clinics in New York City in collaboration with community organizations, allowing for sustainability and scalability. Aim 1 will evaluate the efficacy of a 6-month SMS program for DM management versus an attention control on changes in HbA1c and adherence to DM self-care activities, medications, and appointments at 9 months in adult PEH with uncontrolled DM (n=100). Outcomes will be measured at 0, 3, 6, \&9 months. Aim 2 will assess patients' and providers' attitudes, acceptability, and experience of the program through semi-structured interviews with PEH and providers.
A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the overdose. Intravenous sodium bicarbonate should be used to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate, hyperventilation may also be used. Concomitant use of hyperventilation and sodium bicarbonate should be done with extreme caution, with frequent pH monitoring. A pH >7.60 or a pCO2 <20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/ hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).

In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis generally have been reported as ineffective in tricyclic antidepressant poisoning.
944,749. Hematinics. AMERICAN CYANAMID CO. Feb. 10, 1961, No. 36046/61. Addition to 918,737. Heading A5B. [Also in Division C1] Aqueous ferric hydroxide sols which have a positive charge and are stabilized by means of a potato starch dextrin of specified viscosity, in accordance with the parent Specification are characterized in that they contain approximately 10% Fe, and are used as hematinics to be administered by injection.
The present invention relates to a biomarker for diagnosing chronic rhinosinusitis, a diagnosing composition using the same, and a chronic rhinosinusitis preventing or treating pharmaceutical composition. The increased expression of IKK is observed, compared to a normal person, in nasal epithelial cells of a chronic rhinosinusitis patient, and IKK is over-expressed in mouse nasal epithelial cells by using lentivirus. As a result, an inflammation view is increased when a Sendai virus is infected compared to a normal group. Thus, IKK can be useful as a biomarker for diagnosing chronic rhinosinusitis. Moreover, an inflammation view is decreased by treating an IKK inhibitor in a chronic rhinosinusitis mouse model. Thus, the IKK inhibitor can be useful as a medicine or a health food for preventing or treating chronic rhinosinusitis.
Background and Objectives: Radiation therapy (RT) plays a crucial role in managing prostate cancer, offering effective disease control and improving survival rates in both localized and recurrent cases. However, RT can lead to hemorrhagic cystitis, a significant late complication resulting in chronic morbidity and other health issues. This study aims to evaluate the real-world incidence of radiation-induced hemorrhagic cystitis requiring surgical intervention. Materials and Methods: This retrospective cohort study analyzed data from prostate cancer survivors treated for hematuria at our center between January 2014 and January 2024. Patients were included if cystoscopy identified radiation cystitis as the cause of hematuria. Descriptive statistics were used, and binomial logistic regression analyses with univariate and multivariate analysis were performed to identify risk factors for worse outcomes. Results: Fifty-two patients met the inclusion criteria. The estimated cumulative incidence at a median follow-up of 5.3 years was 4.5%. Among the participants, 21.2% required more than two transurethral bladder fulguration (TUBF) procedures, and 38.5% needed more than two hospital admissions for hematuria management. The median time to the first fulguration was 64 months. Blood transfusions were necessary in 53.8% of cases, and 38.5% required hyperbaric oxygen therapy. Ultimately, 5.8% of the patients underwent cystectomy. Univariate analysis identified ischemic heart disease (IHD) and antiplatelet therapy as significant risk factors (OR: 5.17 and 5.18, respectively), along with longer time to first fulguration (OR: 5.02). Multivariate analysis confirmed antiplatelet therapy (OR: 2.8, p = 0.05) and time to first TUBF (OR: 1.8, p = 0.02) as significant predictors of multiple procedures. Conclusions: Radiation cystitis remains a significant burden on prostate cancer survivors. Patients on antithrombotic agents, those with delayed initial presentations, and those who received radiation as salvage therapy are more likely to experience higher morbidity.
Hepatitis B is one of the public health priorities worldwide, especially in the Southwest China. Our study aimed to investigate the relationship between genotypes and drug resistance mutations among HBV patients in Southwest China, with the objective of providing guidance for clinical antiviral treatment. A total of 4266 chronic hepatitis B (CHB) patients treated in the Qianjiang Hospital of Chongqing University were included in our study from 2014 to 2020. Both genotypes and drug-resistant mutations of CHB patients were determined by polymerase chain reaction (PCR). Genotype B and genotype C were the main HBV genotypes in our study. We found 54 mutation patterns, including 9 single-site mutations and 45 multiple-site mutations, accounting for 57.64% and 42.36%, respectively. rtM204I/V/S (485/1936) was the most common single-site mutation type, and rtL180M + rtM204I/V (482/1936) was the most common multiple-site mutation type. 1372 CHB patients were resistant to LAM + LDT, and 342 CHB patients were resistant to ADV. There was only 1 CHB patient who exhibited resistance to LAM + LDT + ADV + ETV, with a specific mutation pattern of rtA181T + rtT184L + rtM204V. Our study demonstrated trends in genetic mutations and drug resistance in CHB patients to enable timely adjustment of antiviral treatment strategies.
Successfully screened participants will be randomly assigned to KN057 Prophylaxis versus No Prophylaxis at a ratio of 2:1. Participants in Arm 1 (KN057 Prophylaxis) will receive KN057 through the main trial (26 weeks) and extension period (26 weeks) for total of approximately 1 year.
PURPOSE: A composition containing peanut sprout extract is provided to suppress apoptosis and to effectively protect nerve cells. CONSTITUTION: A composition for preventing and treating neurodegenerative disease contains peanut sprout extract as an active ingredient. The peanut sprout is produced by cultivating peanuts. The peanut sprout extract is isolated from a head part of the peanut sprout using an alcohol solvent. The peanut sprout extract contains 8,13-dihydroxy-9,11-octadecadienoic acid. A composition for preventing and treating neurodegenerative diseases contains 8,13-dihydroxy-9,11-octadecadienoic acid as an active ingredient. The neurodegenerative diseases are prevented and treated by suppressing apoptosis of nerve cells.
Participants in the music group will receive headphones with music 30 minutes before surgery. Patients will be able to choose music from a preselected list composed by a team consisting of researchers and dedicated music therapists. The headphones will be removed before entering the operating room. Once in the operating room they will receive earphones after intubation, compatible with the Mayfield and site of operation. The intraoperative music intervention will be continued during the surgical procedure and discontinued just before detubation. The duration of the intraoperative music intervention depends on the duration of surgery and will be documented. After surgery, during recovery at the post-operative care unit (PACU) another 30 minutes of music through headphones will be given. The following 3 days (post-operative day 1, 2 and 3) at the neurosurgical ward they will receive music twice a day for 30 minutes. All participants will further receive standard of clinical care.
A DNA containing the DNA having a base sequence coding for the amino acid sequence of human-origin prostacyclin synthase (PGIS) represented substantially by SEQ ID No. 12; a vector containing the above DNA; a host cell transformed by the above vector; and a process for producing human-origin PGIS by culturing the host cell in a medium. A polypeptide having the amino acid sequence of human-origin PGIS represented substantially by SEQ ID No. 12; and an antibody having a reactivity with the human-origin PGIS. A medicinal composition containing the DNA or the vector containing the DNA. A method of accelerating PGI2 production by introducing the DNA or the vector containing the DNA into a living organism; or a method of treating diseases caused by a reduction in PGI2 production. The invention serves to clarify the primary structure of human-origin PGIS and the base sequence coding for the same. The PGIS and its DNA are useful as a reagent for developing a remedy for circulatory diseases caused by the production imbalance between PGI2 and TXA2 and a diagnostic reagent for determining the internal tissue expression levels of the PGIS or its mRNA. The PGIS, when introduced into a living organism in an affected part specific manner, is utilizable as a remedy for circulatory diseases. The production process is useful for mass-producing human-origin PGIS readily and efficiently. The antibody is useful for purification of human-origin PGIS and immunohistochemical analysis of causes of diseases.
Muscle relaxant (I) consists of a synergistic combination of; (a) a depolarising muscle relaxant to the more rapid component; (b) a non-polarising muscle relaxant as the retard component; (c) a local anaesthetic and (d) a magnesium salt. USE/ADVANTAGE - (I) can be used in gynaecology as a birth aid. It is injected in the cervix and perineum in order to enlarge the cervix relax the perineum, alleviate pain nd accelerate birth. (I) can also be used in the treatment of spastic muscle diseases. Component (a) takes effect within 30-60 seconds. Its effect is prolonged by the action of component (b) after about 3-5 min. The effect of the local anaesthetic and the magnesium ions lasts 30-60min. The agent can be used in approx. 1.4 the dose required by general anaesthesia for muscle relaxation. The risk of rupture of vagina, cerviux or perineum, of foetal hypoxia and the necessity for caesarians are reduced.
Mast cells (MCs) are important intermediates between the nervous and immune systems. The cardiac autonomic nervous system (CANS) crucially modulates cardiac electrophysiology and arrhythmogenesis, but whether and how MC-CANS neuroimmune interaction influences arrhythmia remain unclear. Our clinical data showed a close relationship between serum levels of MC markers and CANS activity, and then we use mast cell stabilizers (MCSs) to alter this MC-CANS communication. MCSs, which are well-known anti-allergic agents, could reduce the risk of ventricular arrhythmia (VA) after myocardial infarction (MI). RNA-sequencing (RNA-seq) analysis to investigate the underlying mechanism by which MCSs could affect the left stellate ganglion (LSG), a key therapeutic target for modulating CANS, showed that the IL-6 and γ-aminobutyric acid (GABA)-ergic system may be involved in this process. Our findings demonstrated that MCSs reduce VA risk along with revealing the potential underlying antiarrhythmic mechanisms.
PURPOSE: Lower urinary tract symptoms (LUTS) are a challenge to the healthy nursing workforce. Nurses confront various objective and subjective nursing workloads which contribute to their LUTS, but less is known about how nursing workloads influence their LUTS. This study is designed to test hypotheses that delayed voiding behaviors mediate the relationships between nursing workloads and LUTS in female nurses.
MATERIALS AND METHODS: This study analyzed the baseline data collected from an ongoing cohort study named Nurse Urinary Related Health Study in China. LUTS of nurses in 20 tertiary hospitals were assessed with the International Consultation on Incontinence Questionnaire‒Female Lower Urinary Tract Symptoms. Objective nursing workloads including working environment, working hours, and working schedule were collected, and perceived stress, the proxy of the subjective nursing workload, was assessed with the Perceived Stress Scale. Delayed voiding behaviors were assessed with 3 questions adapted from the Taiwan Nurse Bladder Survey. Structural equation modeling was used to run the mediation model.
RESULTS: More than half (51%) of 13,191 female nurses had LUTS. Median age was 31 years (IQR 27-37). When delayed voiding behaviors served as a mediator, the direct effects of subjective nursing workload rather than objective nursing workloads on LUTS were significant.
CONCLUSIONS: Nursing workloads influence nurses' LUTS via delayed voiding behaviors. Strategies tailored to delayed voiding behaviors should be developed, and these may work with stress-reducing strategies as the gatekeepers for nurses' bladder health.
PROBLEM TO BE SOLVED: To obtain a medicine which can prevent and treat hypobulia and lowering of spontaneity due to cerebrovascular accidents or depression symptom by formulating a naphthyloxazolidone derivative. SOLUTION: This medicine contains a compound of the formula (R<1> is a lower alkyl substitutable with a cycloalkyl; R<2> is a lower alkyl) or its salt as an active ingredient. As this active ingredient, (R)-3-[6-cyclopropylmethoxy)-2- naphthyl]-5-methoxy-methyl-2-oxazolidone is illustrated. Though it can be orally and parenterally administrated, oral administration is more preferable. The dose is 0.01-250mg/kg/day. Particularly, this medicine is excellent in antireserpine activity in model animals with cerebrovascular accidents, akinetic time- shortening effect in the despair test and effect of improving shuttle box-escaping behavior disease.
Bronchial thermoplasty (BT), an effective treatment for severe asthma, requires heat to reach the airway to reduce the mass of airway smooth muscle cells (ASMCs). Autophagy is involved in the pathological process of airway remodeling in patients with asthma. However, it remains unclear whether autophagy participates in controlling airway remodeling induced by BT. In this study, we aim to elucidate the autophagy-mediated molecular mechanisms in BT. Our study reveal that the number of autophagosomes and the level of alpha-smooth muscle actin (α-SMA) fluorescence are significantly decreased in airway biopsy tissues after BT. As the temperature increased, BT causes a decrease in cell proliferation and a concomitant increase in the apoptosis of human airway smooth muscle cells (HASMCs). Furthermore, increase in temperature significantly downregulates cellular autophagy, autophagosome accumulation, the LC3II/LC3I ratio, and Beclin-1 expression, upregulates p62 expression, and inhibits the AMPK/mTOR pathway. Furthermore, cotreatment with AICAR (an AMPK agonist) or RAPA (an mTOR antagonist) abolishes the inhibition of autophagy and attenuates the increase in the apoptosis rate of HASMCs induced by the thermal effect. Therefore, we conclude that BT decreases airway remodeling by blocking autophagy induced by the AMPK/mTOR signaling pathway in HASMCs.
The present disclosure provides use of OATPlB3 in preparation of a magnetic resonance/near infrared reporter for monitoring and/or in vivo tracking of transplanted cells, and belongs to the technical field of molecular imaging. With OATPlB3 as a reporter molecule, the proliferation. or transplantation. of living target cells or transplanted cells is indirectly reported through near infrared or MRI dye uptake. OATPlB3—mediated, indocyanine green (ICG) uptake has a characteristic of relatively strong fluorescence output in a near infrared band, which can trace cell migration and survival, and, show relatively bright contrast enhancement on Tl weighted MRI, and the survival time of xenograft is traced by the OATPlB3 as a multimodal reporter for tracking cell migration. Therefore, the present disclosure provides the use of OATPlB3 in preparation of a magnetic resonance/near infrared reporter for in vivo tracking and/or monitoring of transplanted cells.
The invention relates to a cefamandole nafate hydrate. The molecular formula of the cefamandole nafate hydrate is C19H17N6NaO6S25H2O. The preparation method of the cefamandole nafate hydrate comprises the following steps of: dissolving cefamandole nafate crude drug in water and placing the dissolved cefamandole nafate crude drug in a crystallizer; adding 5-15 parts of elution agents, cooling the mixture to 2-8 DEG C, separating out solids and then filtering; and rinsing the solids in the elution agents, drying for 3-5 hours at the drying temperature of 10-50 DEG C under a ventilated or vacuum condition to obtain the cefamandole nafate hydrate. The invention also provides a cefamandole nafate for injection, which is prepared by using the cefamandole nafate hydrate as the crude drug. The cefamandole nafate hydrate obtained in the method has the advantages of smooth surface, good stability and high dissolving sped in water. After the cefamandole nafate hydrate is dissolved in the water, the action mechanism and the clinical effect of the cefamandole nafate hydrate are the same as those of cefamandole nafate prepared in the traditional process.